Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norberto Antongiovanni

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Nefrologia|March 21, 2019
Fabry nephropathy. Role of nephrologist and clinical variables associated with the diagnosisSebastián Jaurretche, Norberto Antongiovanni, Fernando Perretta
Case Reports in Nephrology|November 4, 2017
Early Renal Involvement in a Girl with Classic Fabry DiseaseFernando Perretta, Norberto Antongiovanni, Sebastián Jaurretche
Thescientificworldjournal|June 29, 2018
Major Organic Involvement in Women with Fabry Disease in ArgentinaFernando Perretta, Norberto Antongiovanni, Sebastián Jaurretche
Indian Journal of Nephrology|December 5, 2019
Direct Correlation between Age at Diagnosis and Severity of Nephropathy in Fabry Disease PatientsSebastián P A Jaurretche, Norberto Antongiovanni, Fernando Perretta
International Journal of Chronic Diseases|July 26, 2019
Variables Associated with a Urinary MicroRNAs Excretion Profile Indicative of Renal Fibrosis in Fabry Disease PatientsSebastián Jaurretche, Germán Perez, Norberto Antongiovanni, et al.
Nefrologia|February 7, 2026
Urinary VEGF-A165b mRNA expression in Fabry disease: Pilot studySebastián Jaurretche, Germán Perez, Norberto Antongiovanni, et al.
Medicina|June 24, 2017
Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin AmericaDiego Ripeau, Hernán Amartino, Martín Cedrolla, et al.
Molecular Genetics and Metabolism|March 14, 2025
Argentine program of home infusions with enzyme replacement therapy for lysosomal diseases: Results in safety, quality of life and adherenceGuillermo Drelichman, Juan M Politei, Nicolás Fernandez Escobar, et al.
Pediatric Nephrology (Berlin, Germany)|July 11, 2018
Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?Juan Politei, Valeria Alberton, Oscar Amoreo, et al.
Medicina|October 25, 2013
[Guidelines for diagnosis, monitoring and treatment of Fabry disease], Pablo Neumann, Norberto Antongiovanni, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Nefrologia|March 21, 2019
Fabry nephropathy. Role of nephrologist and clinical variables associated with the diagnosisSebastián Jaurretche, Norberto Antongiovanni, Fernando Perretta
Case Reports in Nephrology|November 4, 2017
Early Renal Involvement in a Girl with Classic Fabry DiseaseFernando Perretta, Norberto Antongiovanni, Sebastián Jaurretche
Thescientificworldjournal|June 29, 2018
Major Organic Involvement in Women with Fabry Disease in ArgentinaFernando Perretta, Norberto Antongiovanni, Sebastián Jaurretche
Indian Journal of Nephrology|December 5, 2019
Direct Correlation between Age at Diagnosis and Severity of Nephropathy in Fabry Disease PatientsSebastián P A Jaurretche, Norberto Antongiovanni, Fernando Perretta
International Journal of Chronic Diseases|July 26, 2019
Variables Associated with a Urinary MicroRNAs Excretion Profile Indicative of Renal Fibrosis in Fabry Disease PatientsSebastián Jaurretche, Germán Perez, Norberto Antongiovanni, et al.
Nefrologia|February 7, 2026
Urinary VEGF-A165b mRNA expression in Fabry disease: Pilot studySebastián Jaurretche, Germán Perez, Norberto Antongiovanni, et al.
Medicina|June 24, 2017
Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin AmericaDiego Ripeau, Hernán Amartino, Martín Cedrolla, et al.
Molecular Genetics and Metabolism|March 14, 2025
Argentine program of home infusions with enzyme replacement therapy for lysosomal diseases: Results in safety, quality of life and adherenceGuillermo Drelichman, Juan M Politei, Nicolás Fernandez Escobar, et al.
Pediatric Nephrology (Berlin, Germany)|July 11, 2018
Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?Juan Politei, Valeria Alberton, Oscar Amoreo, et al.
Medicina|October 25, 2013
[Guidelines for diagnosis, monitoring and treatment of Fabry disease], Pablo Neumann, Norberto Antongiovanni, et al.
Pageof 1